⌘K
Loading ticker…
As of 2026-08-21, ProKidney Corp. Class A Ordinary Shares (PROK) has a 3-month relative strength percentile of 32 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 42. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.6%, relative volume 1.52×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PROK is in a stage 4 downtrend, week 7. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -2.7% / -19.0%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
PROK is held by 2 ETFs as of May 2026. Top owner: SCHA at 0.00% weight, $924K notional.
Held by 4 ETFs · $3M across latest filings · largest weight 0.64% (BBC).
Top 2 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.00% | $924K | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $119K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Operating margin unavailable
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PROK Jan avg: 2.92% median: -6.99% win: 25% σ: 34.21% n: 4 2022-07-13 → 2026-07-31 | PROK Feb avg: 6.05% median: 12.61% win: 75% σ: 21.73% n: 4 2022-07-13 → 2026-07-31 | PROK Mar avg: -12.85% median: -11.63% win: 25% σ: 13.91% n: 4 2022-07-13 → 2026-07-31 | PROK Apr avg: 4.13% median: 3.61% win: 75% σ: 17.49% n: 4 2022-07-13 → 2026-07-31 | PROK May avg: 18.76% median: 12.46% win: 50% σ: 38.54% n: 4 2022-07-13 → 2026-07-31 | PROK Jun avg: -10.94% median: -12.95% win: 25% σ: 17.33% n: 4 2022-07-13 → 2026-07-31 | PROK Jul avg: 73.41% median: 14.02% win: 60% σ: 165.37% n: 5 2022-07-13 → 2026-07-31 | PROK Aug avg: -11.94% median: -8.62% win: 25% σ: 15.87% n: 4 2022-07-13 → 2026-07-31 (current) | PROK Sep avg: -17.56% median: -13.07% win: 25% σ: 21.49% n: 4 2022-07-13 → 2026-07-31 | PROK Oct avg: -10.58% median: -2.17% win: 50% σ: 40.13% n: 4 2022-07-13 → 2026-07-31 | PROK Nov avg: -2.34% median: -3.46% win: 50% σ: 22.10% n: 4 2022-07-13 → 2026-07-31 | PROK Dec avg: -8.34% median: -7.30% win: 50% σ: 14.24% n: 4 2022-07-13 → 2026-07-31 |